相关实验视频
Updated: Jun 17, 2025

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
826
工程P2Y12-过度表达的细胞膜包裹的纳米颗粒用于功能逆转蒂卡格勒罗和克洛皮多格勒罗的功能逆转
Xiao Guo1, Siping Ye1, Xiaoyu Cheng2
1College of Pharmacy, Beihua University, Jilin 132013, PR China.
Nano letters
|August 14, 2024
概括
新的细胞膜包裹纳米颗粒 (CM-NP) 可以快速逆转P2Y12抑制剂,一种类型的抗血小板药物的作用. 这一突破为服用这些关键药物的患者管理出血并发症提供了潜在的解决方案.
科学领域:
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
- 纳米技术纳米技术
背景情况:
- 抗血小板药物,特别是P2Y12受体抑制剂,对于预防血栓性疾病至关重要.
- 长期使用这些药物会增加心血管患者出血的风险.
- 目前的治疗方法缺乏抗血小板药物效应的快速逆转剂.
研究的目的:
- 开发一种快速逆转P2Y12抑制剂的方法.
- 为了解决与抗血小板治疗相关的出血并发症管理的未满足的临床需求.
主要方法:
- 细胞膜包裹纳米颗粒 (CM-NP) 的制造.
- 利用基因工程的293T细胞过度表达纳米粒子膜的P2Y12受体.
- 研究了CM-NP在逆转P2Y抑制剂作用中的有效性.
主要成果:
- 成功开发出能够逆转P2Y12抑制剂的CM-NP.
- 证明了CM-NP作为治疗策略的潜力.
- 展示了一种管理出血风险的新方法.
结论:
- CM-NP代表了一种有前途的策略,用于管理P2Y抑制剂引起的出血并发症.
- 这种方法可以在临床实践中显著提高抗血小板药物的安全性.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
501
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
501
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
162
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
162

